Clinical TrialID 2578
A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes
NCT00000645
HIV Infections
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 2578
- Evidence Id
- 2578
- Core Evidence Id
- 2578
- Source Clinical Trial Id
- 2557
- Herb2 Clinical Trial Id
- HBCT002557
- Nct Id
- NCT00000645
- Title
- A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes
- Status
- Completed
- Phase
- Phase 1
- Study Result
- No
- Study Condition
- HIV Infections
- Study Type
- Interventional
- Study Design
- Allocation: |Intervention Model: |Masking: NONE|Primary Purpose: TREATMENT
- Intervention
- DRUG: Hypericin
- Intervention Allocation
- Intervention Model
- Intervention Mask
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 32
- Outcome Measure
- Sponsor Collaborator
- National Institute of Allergy and Infectious Diseases (NIAID)|VIMRx Pharmaceuticals
- Funded By
- NIH
- Location
- Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, 02215, United States|University of Minnesota, ACTU, Minneapolis, Minnesota, United States|NY Univ. HIV/AIDS CRS, New York, New York, 10016, United States
- Other Id
- ACTG 150|11125
- Start Date
- Primary Completion Date
- Completion Date
- 1994-10
- First Posted
- 2001-08-31
- Results First Posted
- Last Update Posted
- 2021-11-03
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT00000645
- Title Cn
- Title En
- A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes
- Bilingual Status
- semi_complete